CAS9 Technology Market: Product Type (Consumables and Vectors), Application (Genome Engineering, Disease Models and In Vitro Genetic Depletion), Delivery Method (Physical Delivery Methods, Viral Delivery Methods and Non-Viral Delivery Methods) and End User (Biotechnology & Pharmaceutical Companies and Academic & Research Institutes) and Region - Global Forecast Till 2030
ID: MRFR/ICT/1532-CR | 153 Pages | Published By Ankit Gupta on February 2019
Speak to Analyst
Request a Free Sample
CAS9 Technology Market
The global CAS9 technology market size is USD 6.72 Billion expected to record a CAGR of 11.30% during the review period (2022–2030).
$ 6.72 Billion
11.30%
North America
2022-2030
CAS9 Technology Market Snapshot:
A strong commercial interest and rising application opportunities to boost the global CAS9 technology market in the forthcoming years. The CAS9 technology market is expected to grow at a compound annual growth rate of 11.30% between 2022 and 2030. Emergence of genome editing or gene editing with engineered nucleases has taken genetic engineering to the next level. CAS9 technology is quickly gaining prominence as a genome editing tool. Advanced countries in North America and Europe are witnessing a faster uptake of the technology. Asia Pacific is also likely to present lucrative growth opportunities to market players during the review period.
This MRFR report offers a detailed analysis of the CAS9 technology market. It also includes five-year revenue analysis, ending in 2030. The report starts with a market introduction where point such as scope of study, research objective and list of assumptions are discussed. This is followed by a through discussion on market dynamics. Next, an in-depth market segment and segment analysis is furnished. This report also includes a market competitive landscape, which covers some of the top companies operating in the CAS9 technology market.
CAS9 Technology Market Companies Covered:abm Inc., Cellecta, Inc., CRISPR Therapeutic, GenScript, Danaher Corporation (Integrated DNA Technologies, Inc.), Intellia Therapeutics, Inc., New England Biolabs, GE Healthcare, OriGene Technologies, Inc. Takara Bio, Inc., Lonza Group, Thermo Fisher Scientific, AstraZeneca, PLC, Merck KGaA, and Bio-Rad Laboratories, Inc.
The report offers insights into the leading market players and presents an assessment of their current market position. Company information with regards to revenue, segmental share, geographical income, SWOT, growth strategies, new product launch, M&A activities, and the latest R&D initiatives is also available in the report
Research Methodology:MRFR employs a range of scrupulously chosen methods to build a research model for drawing mission-critical insights. Use of primary methods such as personal interviews with industry decision makers allows to get an inside look. Then, the findings from primary research methods are avouched by secondary research methods such as annual reports, annual reports, SEC filings, etc. To guarantee transparency and adhere to provide reliable market data, top-down and bottom-up approaches are integrated into the research model. This allows data analysts to offer recognition of many pivotal market figures. These figures are then used to postulate weighty analysis coinciding with timely insights.
Other Description:
- Market Denomination- USD Mn
- Base Year- 2017
- Forecast Period- from 2018 to 2023
For the scope of the research, MRFR’s report offers a comprehensive segmental analysis of the global market for CAS9 technology
Product Type:
- Consumables
- Vectors
Application:
- Genome engineering
- Disease models
- In vitro genetic depletion
Delivery Method:
- Physical delivery methods
- Viral delivery methods
- Non-viral delivery methods
End User:
- Biotechnology & pharmaceutical companies
- Academic & research institutes
By Region:
- North America
- Europe
- Asia Pacific
- The Middle East & Africa (MEA)
- Latin America.
Intended Audience:
- Pharmaceutical & Biopharmaceutical companies
- Biotechnology Companies
- Government Research Laboratories
- Independent Research Laboratories
- Market Research and Consulting Service Providers
- Medical Research Laboratories
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2030: USD 6.72 Billion |
| CAGR | 11.30% |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product Type, Delivery Method, Application |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Cellecta, Inc., abm Inc., GenScript, CRISPR Therapeutic, Intellia Therapeutics, Inc., GE Healthcare, Takara Bio, Inc., AstraZeneca, PLC, Merck KGaA, Bio-Rad Laboratories, Inc., Danaher Corporation (Integrated DNA Technologies, Inc.), New England Biolabs, OriGene Technologies, Inc., Lonza Group, and Thermo Fisher Scientific |
| Key Market Opportunities |
|
| Key Market Drivers | Growing awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth. |
Frequently Asked Questions (FAQ) :
The global CAS9 technology market is expected to record a CAGR of 11.30% during the review period (2022–2030).
Growing awareness regarding biotechnology techniques and products and the increasing acceptance of gene therapy-based treatments are the major driving factors for the CAS9 technology market growth.
the associated risk factors and high prices are one of the impeding factors for the growth of the CAS9 technology market.
The North American region is expected to acquire the largest market share at 11.52% CAGR.
The physical delivery method segment of the CAS9 technology market is expanding at a 29.11% CAGR over the review period.
A few significant players of the CAS9 technology market are tech giants such as Thermo Fisher Scientific, AstraZeneca, PLC, Merck KGaA, and Bio-Rad Laboratories, Inc, among others.
The genome engineering segment is expected to record the highest growth over the assessment period.
